What lower the development of nanodrug?

  • Chong Qiu State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences
Ariticle ID: 460
126 Views, 94 PDF Downloads

Abstract

Only a few nanomedicines have entered clinical application after over a decade and billions of dollars of investments in nanoscience and nanotechnology around the world. So, what lower the development of nanodrug? Recently, at our recent Editorial and Editorial Advisory Board meeting, we asked ourselves to address these questions and accelerate the development of nano pharmaceuticals. We will work with leaders in the area of drug supply to share our experiences and compare efforts around the world.

References

[1] Sönksen M, Kerl K, Bunzen H. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors. Medicinal Research Reviews. 2021, 42(1): 374-398. doi: 10.1002/med.21844

[2] Tawfik M, Chen F, Goldberg JL, et al. Nanomedicine and drug delivery to the retina: current status and implications for gene therapy. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2022, 395(12): 1477-1507. doi: 10.1007/s00210-022-02287-3

[3] Sun Q, Zhou Z, Qiu N, et al. Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization. Advanced Materials. 2017, 29(14). doi: 10.1002/adma.201606628

[4] Cheng Z, Li Y, Zhao D, et al. Nanocarriers for intracellular co-delivery of proteins and small-molecule drugs for cancer therapy. Frontiers in Bioengineering and Biotechnology. 2022, 10. doi: 10.3389/fbioe.2022.994655

[5] Qiu C, Xia F, Zhang J, et al. Advanced Strategies for Overcoming Endosomal/Lysosomal Barrier in Nanodrug Delivery. Research. 2023, 6. doi: 10.34133/research.0148

[6] Such GK, Yan Y, Johnston APR, et al. Interfacing Materials Science and Biology for Drug Carrier Design. Advanced Materials. 2015, 27(14): 2278-2297. doi: 10.1002/adma.201405084

[7] Lönn P, Kacsinta AD, Cui XS, et al. Enhancing Endosomal Escape for Intracellular Delivery of Macromolecular Biologic Therapeutics. Scientific Reports. 2016, 6(1). doi: 10.1038/srep32301

[8] Gilleron J, Querbes W, Zeigerer A, et al. Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape. Nature Biotechnology. 2013, 31(7): 638-646. doi: 10.1038/nbt.2612

[9] Qiu C, Wu Y, Guo Q, et al. Preparation and application of calcium phosphate nanocarriers in drug delivery. Materials Today Bio. 2022, 17: 100501. doi: 10.1016/j.mtbio.2022.100501

[10] Qiu C, Wu Y, Shi Q, et al. Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy. International Journal of Biological Sciences. 2023, 19(3): 789-810. doi: 10.7150/ijbs.79328

Published
2024-01-08
How to Cite
Qiu, C. (2024). What lower the development of nanodrug?. Materials Technology Reports, 2(1), 460. https://doi.org/10.59400/mtr.v2i1.460
Section
Editorial